Altimmune Appoints Raymond Jordt as Chief Business Officer
Mr. Jordt brings over 25 years of industry experience in corporate strategy and business developmentGAITHERSBURG, Md., Jan. 04, 2023 (GLOBE...
Day: January 4, 2023
New Executive Leadership Team Appointed to Accelerate XOMA’s Differentiated Royalty Monetization Strategy
Owen Hughes appointed Executive Chairman of the Board of Directors and Brad Sitko joins as Chief Investment Officer EMERYVILLE, Calif., Jan....
Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
Registration Stability Batch for VP-102 Completed and Placed on Stability Process Validation Batches Successfully Manufactured Verrica Reaffirms its Expected Q1...
Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
GAITHERSBURG, Md., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that Dr....
Kane Biotech Announces First Distribution Agreement for its coactiv+™ Antimicrobial Hydrogel
Salud Pharma to launch product in Colombia, Panama, and Costa RicaWINNIPEG, Manitoba, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Kane Biotech...
Vivos Therapeutics Receives FDA 510(k) Clearance of its Flagship DNA Oral Appliance for Treatment of Obstructive Sleep Apnea
Approval represents third FDA clearance for Vivos’ oral appliances and first clearance specifically recognizing Vivos’ proprietary core technologyLITTLETON, Colo., Jan. 04,...
VitalHub Announces Five Year Licensing Contract With Wirral University Teaching Hospital
TORONTO, Jan. 04, 2023 (GLOBE NEWSWIRE) -- VitalHub Corp. (the “Company” or “VitalHub”) is pleased to announce a five-year licensing...
Biogen and Alcyone Therapeutics Announce License and Collaboration Agreement to Evaluate a Novel Device to Improve Patient Experience and Access to Neurological ASO Therapies
Alcyone’s ThecaFlex DRx™ System is an implantable medical device in development for intrathecal drug deliveryCAMBRIDGE, Mass. and LOWELL, Mass., Jan. 04,...
Aravive Announces Complete Enrollment in the Global Registrational Phase 3 AXLerate-OC Trial for Platinum-Resistant Ovarian Cancer
Topline data expected mid-2023Potential Biologics License Application (BLA) submission end of 2023HOUSTON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Aravive, Inc....
Fulcrum Therapeutics Provides Business Update and 2023 Outlook
― FTX-6058 granted Fast Track Designation for sickle cell disease (SCD) from FDA in December 2022 ―― Completed enrollment in...